Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PollenBerry is a dietary supplement developed by Graminex LLC that combines water-soluble flower pollen extract (specifically the G60 Flower Pollen Extract fraction) with cranberry powder. Each capsule is formulated with 42 mg of the pollen extract and 125 mg of cranberry powder. It is primarily marketed as a natural health product for urinary tract health, with a specific focus on preventing recurrent urinary tract infections (UTIs) and managing stress-induced urinary incontinence in women. PollenBerry has received regulatory recognition from Health Canada as a traditional herbal medicine. Clinical studies have demonstrated its efficacy in reducing urinary leakage volume in women aged 40-75. As a botanical combination, its mechanism of action is attributed to the collective properties of its ingredients rather than a single molecular target.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on PollenBerry.